Skip to content

Tegileridine improves postoperative pain in patients undergoing day surgery for laparoscopic cholecystectomy: A randomized controlled trial

Tegileridine improves postoperative pain in patients undergoing day surgery for laparoscopic cholecystectomy: A randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111661
Enrollment
Unknown
Registered
2025-11-04
Start date
2026-06-01
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholecystolithiasis

Interventions

The sufentanil group (Group S):Thirty minutes before the surgery was completed, sufentanil was injected intravenously at a dose of 0.1 micrograms per kilogram.
The tegrilide group (Group T):Thirty minutes before the surgery was completed, 1 milligram of tegretol was injected intravenously.

Sponsors

The Third People's Hospital Yibin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients scheduled for day surgery for cholecystectomy; (2) ASA I-III; (3) 18-65 years old.

Exclusion criteria

Exclusion criteria: (1) The patient refused; (2) Patients allergic to tegrilide; (3) Patients who participated in other interventional studies within three months.

Design outcomes

Primary

MeasureTime frame
The numerical pain score (NRS) when moving for the first day after the operation;

Secondary

MeasureTime frame
The NRS score at rest on the first day after the operation;The incidence of postoperative nausea;The incidence of postoperative vomiting.;The incidence of postoperative dizziness;The incidence of moderate to severe pain on the first day after surgery;Patient satisfaction with pain control;Quality of Recovery Score (QOR-15) of Postoperative Day 1;

Countries

China

Contacts

Public ContactLi Xiong

The Third People's Hospital Yibin

18606108@qq.com+86 185 0831 3321

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026